Gland Pharma Limited

Gland Pharma Limited, established in 1978, is a prominent Indian pharmaceutical company specializing in the manufacturing and sale of injectable formulations. Headquartered in Hyderabad, Telangana, India, the company has expanded its global footprint, exporting to over 60 countries, including the United States, Europe, Canada, Australia, and New Zealand.

The company operates as a subsidiary of Shanghai Fosun Pharmaceutical (Group) Co. Ltd., a global pharmaceutical major. As of March 13, 2026, Gland Pharma's stock is listed on the National Stock Exchange of India under the ticker symbol GLAND, with a market capitalization of approximately $3.0 billion USD. The company employs over 4,300 individuals, reflecting its significant presence in the pharmaceutical manufacturing sector.

Gland Pharma operates seven manufacturing facilities across India, comprising four for finished formulations and three for active pharmaceutical ingredients (APIs). These facilities are strategically located in Hyderabad and Visakhapatnam, Andhra Pradesh, ensuring efficient production and distribution capabilities.

The company's manufacturing plants are equipped with state-of-the-art technology and adhere to current Good Manufacturing Practices (cGMP). They specialize in the production of sterile injectables, oncology, and ophthalmic products, focusing on complex injectables such as New Chemical Entity-1s (NCE-1s), First-to-File products, and 505(b)(2) filings.

Gland Pharma's leadership team is headed by Executive Chairman Mr. Srinivas Sadu, who has been instrumental in steering the company's strategic direction. The Chief Executive Officer (CEO) is Mr. Shyamakant Giri, who joined the company in 2025. The Chief Financial Officer (CFO) is Mr. Ravi Shekhar Mitra, who has been with the company since 2024.

Other key executives include Mr. Satnam Singh Loomba, Chief Operating Officer, and Mr. Shriniwas P. Dange, Head of Investor Relations. The Board of Directors comprises independent directors such as Mr. Udo Johannes Vetter, Mr. Essaji Goolam Vahanvati, and Ms. Naina Lal Kidwai, ensuring a diverse and experienced governance structure.

Gland Pharma has established a strong presence in regulated markets, including the United States, Europe, the United Kingdom, Australia, and Japan. In May 2024, the company received approval from the U.S. Food and Drug Administration (FDA) for its generic Edaravone injection, a treatment for amyotrophic lateral sclerosis. In April 2024, the FDA approved Cetrorelix Acetate for Injection, 0.25 mg/vial, Single-Dose Vial, further expanding Gland Pharma's portfolio in the U.S. market.

In June 2025, the company received an Establishment Inspection Report from the FDA for its JNPC facility in Visakhapatnam, India, indicating compliance with FDA standards. Gland Pharma's adherence to international regulatory standards, including those of the European Medicines Agency (EMA) and the Therapeutic Goods Administration (TGA) in Australia, underscores its commitment to quality and compliance in these markets.

Gland Pharma has made significant inroads into emerging markets across Africa, Latin America, and Southeast Asia. The company's adherence to World Health Organization (WHO) prequalification standards has facilitated access to these regions, enabling the supply of high-quality injectable formulations to meet diverse healthcare needs.

Gland Pharma's geographic strategy emphasizes diversification across multiple regions, mitigating concentration risk and enhancing global market presence. The company's expansion into regulated markets, coupled with its focus on emerging markets, reflects a balanced approach to growth and risk management. This strategic direction positions Gland Pharma to leverage opportunities across different geographies, ensuring sustainable growth and resilience in the global pharmaceutical landscape.

Gland Pharma's facilities are registered with the U.S. FDA, and the company has a history of approved Abbreviated New Drug Applications (ANDAs) and Drug Master File (DMF) filings. The receipt of an Establishment Inspection Report from the FDA for its JNPC facility in Visakhapatnam in June 2025 indicates compliance with FDA standards. The company's commitment to quality and regulatory compliance is further demonstrated by its adherence to current Good Manufacturing Practices (cGMP) across its manufacturing facilities.

Gland Pharma's manufacturing facilities comply with World Health Organization (WHO) Good Manufacturing Practices (GMP) and European Union (EU) GMP standards. This compliance ensures that the company's products meet international quality standards, facilitating access to global markets and reinforcing its reputation as a reliable supplier of injectable formulations.

In India, Gland Pharma holds manufacturing licenses from the Central Drugs Standard Control Organisation (CDSCO) and has obtained approvals from state drug controllers. The company also possesses export No Objection Certificates (NOCs), enabling it to export pharmaceutical products to various international markets. These regulatory approvals underscore Gland Pharma's compliance with Indian pharmaceutical regulations and its capability to meet global standards.

As of March 28, 2026, there are no publicly available records of Form 483 observations, warning letters, or import alerts issued to Gland Pharma by the FDA. The company's proactive approach to regulatory compliance and quality assurance has contributed to its strong standing in international markets.

Gland Pharma operates in a competitive landscape with key players such as Sun Pharmaceutical Industries Ltd., IPCA Laboratories Ltd., and Emcure Pharmaceuticals Ltd. While Gland Pharma holds a leading position in the production of injectable formulations, particularly in complex injectables, it faces competition from these established companies in overlapping therapeutic categories. The company's focus on high-quality, affordable products and its global distribution network provide a competitive edge in the market.

Gland Pharma's key differentiators include its specialization in complex injectables, a robust research and development pipeline, and a strong commitment to quality and regulatory compliance. The company's diverse product portfolio across various therapeutic segments and delivery systems, coupled with its focus on sterile injectables, oncology, and ophthalmics, distinguishes it in the pharmaceutical industry.

Gland Pharma's current strategic direction focuses on the development and manufacturing of generic injectables, with an emphasis on complex formulations and contract development and manufacturing organization (CDMO) services. The company's future outlook includes expanding its presence in regulated and emerging markets, enhancing its product portfolio, and leveraging its manufacturing capabilities to meet global healthcare needs.

Gland Pharma has a strong track record in the pharmaceutical industry, with a consistent export volume of $262.0 million USD across 5,302 shipments from 2022 to 2026. The company's reliability is evidenced by its leading market positions in products such as Heparin, Enoxaparin, Syringes, and Ketorolac, with market shares of 10.8%, 11.8%, 17.2%, and 9.1%, respectively. These indicators reflect Gland Pharma's capacity to meet global demand and its commitment to quality and consistency.

Importers should verify the following certifications to ensure product quality and regulatory compliance:

• FDA Registration: Confirm the company's facilities are registered with the U.S. FDA.

• WHO-GMP Certification: Ensure manufacturing facilities comply with WHO Good Manufacturing Practices.

• EU GMP Certification: Verify adherence to European Union Good Manufacturing Practices.

• ISO Certification: Check for relevant ISO certifications related to quality management systems.

These certifications can typically be verified through the company's official website or by contacting the respective regulatory bodies.

Importers should undertake the following steps